Name | SF0166 |
---|
Description | SF0166 is a topically administered αvβ3 integrin antagonist, inhibits integrin-ligand interactions with IC50 of 0.6 nM to 13 nM for human αvβ3, αvβ6, and αvβ8; inhibits cellular adhesion to vitronectin across human, rat, rabbit, and dog cell lines with IC50 of 7.6 pM-76 nM; significantly decreases neovascularization in the oxygen-induced retinopathy mouse models. Other Indication Phase 2 Clinical |
---|---|
References | References 1. Askew BC, et al. J Pharmacol Exp Ther. 2018 May 31. pii: jpet.118.248427. View Related Products by Target Integrin Other Indication |
Molecular Formula | C23H27F2N5O4 |
---|---|
Molecular Weight | 475.497 |